Loading…
← CockpitCompetitor Analysis › NATCOPHARM.NS NATCO PharmaOpen in the cockpit ↗

NATCO PharmaNATCOPHARM.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Specialty generics maker known for complex oncology drugs and aggressive patent-challenge (Para IV) launches in the US.

≈ India's Para IV specialist, a smaller TevaMomentum weak 22
Mkt cap
$1.73B
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$7.36M
20-day average traded
Fwd P/E
19.1×
forward earnings
ROIC−WACC
-8.7 pp
WACC 13.1%
Hurdle
+1 pp
Req g minus delivered
Next earnings
91 days
17 Feb 2027
Close · INR₹820.60
1D-0.3%
1W+1.4%
1M+2.5%
3M-8.7%
6M-27.4%
YTD-9.1%
1Y-0.2%
ATR %2.8%
Beta0.84
52w lowhigh33.1% off high

What NATCO Pharma does

Specialty generics maker known for complex oncology drugs and aggressive patent-challenge (Para IV) launches in the US.

Relies on a small number of high-value US launches, typically in cancer treatment, so earnings jump when a launch is permitted and fall as competitors enter. The India business sells branded cancer drugs to hospitals. Founder V C Nannapaneni leads the company.

In one line: India's Para IV specialist, a smaller Teva.

Products and services

  • Oncology generics
  • Complex generic (Para IV) launches
  • Domestic branded formulations

Customers

  • US pharmacy distributors/partners
  • Indian oncology hospitals

Where it sits in the supply chain

  • API/formulation R&D
  • Complex generic manufacturing
  • US/global generic launches

What could go right

  • First-to-file exclusivity launches
  • Oncology generics growth

What could go wrong

  • Litigation/settlement outcome risk
  • Revenue lumpiness from exclusivity windows

Moat: narrow (IP / patents, process know-how). Expertise in complex generic litigation and first-to-file exclusivity wins are hard to replicate.

Headquarters: Hyderabad, India · Founded: 1981 · Employees: 5,060

Named competitors

NATCO Pharma at a glance

Size NATCO Pharma (NATCOPHARM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.73B, the 420th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹820.60 on 18 Nov 2026.

Performance Over six months the shares fell 27.4%, against +1.8% for the median peer and +3.8% for the India market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue fell 29.6% over the last twelve months (peer median +6.8%); the operating margin is 17.4% (peer median 7.8%).

Valuation It trades at 19.1× forward earnings against a peer median of 19.7× (9th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.7 points below its cost of capital (13.1% WACC).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 103NATCOPHARM.NS 71
Six months, rebased to 100: NATCO Pharma against the median of its 20 peers (local-currency closes).

NATCO Pharma financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹30.9B₹40.5B₹44.1B₹39.8B₹27.0B
Revenue growth—-8%+11%+47%—
Gross profit₹15.8B₹21.7B₹26.4B₹22.9B₹12.0B
EBITDA₹7.31B₹14.9B₹22.5B₹18.2B₹9.69B
Net income₹8.29B₹14.2B₹18.9B₹13.9B₹7.15B
Free cash flown/a₹16.3B₹14.3B₹9.13B₹7.38B
Capital expendituren/a₹3.91B₹5.12B₹3.59B₹2.06B
Total debt₹10.3B₹7.14B₹2.79B₹3.71B₹1.76B

Quarterly statements and history in the cockpit →

NATCO Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%688166MAZEFAE300723CAPLIPOINT600993INDGNAGIO9989300357600664ETON3933NATCOPHARM.NS6-month return →1-month return →
Up and to the right = strong over both horizons. NATCO Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×688166FAE300723CAPLIPOINT600993INDGN9989300357ETON39331681301015ZYMENATCOPHARM.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. NATCO Pharma is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%688166FAE300723600664ETONNATCOPHARM.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. NATCO Pharma is the large dot.

NATCO Pharma competitors and peer comparison

Head to head with its named competitors (NATCOPHARM.NS vs DRREDDY.NS vs CIPLA.NS vs BIOCON.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
NATCO Pharma NATCOPHARM.NS$1.73B-27%-30%17%19.1×20.5%
Dr. Reddy's Laboratories DRREDDY.NS$12.5B+5%-4%9%32.0×30.7%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%
Biocon BIOCON.NS$6.31B-15%+6%8%61.3×n/a

How NATCO Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

NATCO Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureNATCOPHARM.NSPeer medianRank in peer set
1-month return+2.5%-0.3%9th highest of 21
6-month return-27.4%+1.8%3rd lowest of 20
Distance from 52-week high-33.1%-30.6%10th lowest of 21
Revenue growth (TTM)-29.6%+6.8%2nd lowest of 20
Operating margin17.4%7.8%5th highest of 20
Forward P/E19.1×19.7×9th cheapest of 18
Growth the price implies (Req g, 7 yrs)20.5%3.7%5th most demanding of 16
Growth delivered (Del g)+19.0%+8.2%3rd highest of 16
Hurdle (Req g minus delivered)+1.5 pp-6.2 pp7th most demanding of 16
ROIC minus cost of capital-8.7 pp+1.2 pp6th lowest of 21
EV / EBITDA21.4×18.1×4th most expensive of 8
Net debt / EBITDA-0.7×-1.1×3rd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Shenzhen Hepalink Pharmaceutical 9989.HKHong Kong$1.78B-13%-1%8%8.7×-0.4%-0.2%
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%

Questions

Who are NATCO Pharma's main competitors?
Named competitors: Dr. Reddy's (DRREDDY.NS), Cipla (CIPLA.NS), Biocon (BIOCON.NS). The cockpit's measured peer set (industry) also includes BrightGene Bio-Medical Technology (688166.SS), Maze Therapeutics (MAZE), Faes Farma (FAE.MC), ApicHope Pharmaceutical (300723.SZ), Caplin Point Laboratories (CAPLIPOINT.NS), Mayinglong Pharmaceutical (600993.SS).
Is NATCO Pharma expensive compared with its peers?
On forward p/e it trades at 19.1× against a peer median of 19.7×, 9th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has NATCO Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -27.4% against +1.8% for the median peer; over one year -0.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.